Coxsackievirus A6 U.K. Genetic and Clinical Epidemiology Pre- and Post-SARS-CoV-2 Emergence

• Published in: Pathogens (Basel) Vol. 13; no. 11; p. 1020
• Main Authors: Joyce, Alice M, Hill, Jack D, Tsoleridis, Theocharis, Astbury, Stuart, Berry, Louise, Howson-Wells, Hannah C, Allen, Nancy, Canning, Ben, Jones, Carl B, Clark, Gemma, Irving, William L, Tarr, Alexander W, McClure, C Patrick
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 20.11.2024; MDPI
• Subjects: COVID-19; Coxsackievirus; coxsackievirus A6; Coxsackievirus infections; Coxsackieviruses; CVA6; Disease transmission; enterovirus; Epidemics; Epidemiology; Foot-and-mouth disease; Gene sequencing; genetic epidemiology; Genetic relationship; Genomes; Hand-foot-and-mouth disease; Health aspects; HFMD; Infections; Medical research; Medicine, Experimental; Meningitis; Mortality; Nucleic acids; Pandemics; Phylogenetics; Phylogeny; Severe acute respiratory syndrome coronavirus 2; Skin; Statistical analysis; Surveillance; Viral diseases; VP1 protein; United Kingdom; Europe; Japan; China; United Kingdom > UK; hand, foot and mouth disease; HFMD; enterovirus; coxsackievirus A6; CVA6; genetic epidemiology
• DOI: 10.3390/pathogens13111020
• ISSN: 2076-0817

Coxsackievirus A6 (CVA6) has become increasingly clinically relevant as a cause of Hand, Foot and Mouth Disease (HFMD) globally since 2008. However, most laboratories do not routinely determine the enteroviral type of positive samples. The non-pharmaceutical measures introduced to curb transmission during the COVID-19 pandemic may also have perturbed CVA6 epidemiology. We thus aimed to determine the prevalence, clinical presentation and genetic relationship of CVA6 across three complete epidemic seasons: one pre-SARS-CoV-2 emergence and two post-SARS-CoV-2 emergence in our regional healthcare setting. Surplus diagnostic nucleic acid from diagnosed enteroviral positives diagnosed between September and December of 2018 and between May 2021 and April of 2023 was subject to VP1 gene sequencing to determine the CVA6 cases and interrogate their phylogenetic relationship. The confirmed CVA6 cases were also retrospectively clinically audited. CVA6 infections were identified in 33 and 69 individuals pre- and post-pandemic, respectively, with cases peaking in November of 2018 and 2022, but in October of 2021. HFMD was the primary diagnosis in 85.5% of the post-pandemic cases, but only 69.7% of the pre-pandemic cases, where respiratory and neurological symptoms (45.5% and 12.1%, respectively) were significantly elevated. A complete VP1 sequence was retrieved for 94% of the CVA6 cases, revealing that studied infections were genetically diverse and suggestive of multiple local and international transmission chains. CVA6 presented a significant clinical burden in our regional U.K. hospital setting both pre- and post-pandemic and was subject to dynamic clinical and genetic epidemiology.